STRO (STOCKS)
Sutro Biopharma, Inc.
$30.200000
+1.400000 (+4.86%)
Prev close: $28.800000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jane Chung
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $502.91M
- Employees
- 244
- P/E (TTM)
- -1.84
- P/B (TTM)
- -7.48
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
13
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-2.94 | $-3.85 | +0.9063 | +23.56% |
|
Dec 2025 (Q4)
|
$-5.29 | $-4.43 | -0.8591 | -19.39% |
|
Sep 2025 (Q3)
|
$-6.70 | $-4.23 | -2.4727 | -58.49% |
|
Jun 2025 (Q2)
|
$-1.40 | $-4.10 | +2.7026 | +65.88% |
Financial Statements
| Revenues | $99.61M |
| Benefits Costs and Expenses | $253.33M |
| Costs And Expenses | $253.33M |
| Operating Expenses | $219.12M |
| Research and Development | $151.37M |
| Other Operating Expenses | $67.74M |
| Operating Income/Loss | -$119.51M |
| Income/Loss From Continuing Operations After Tax | -$153.60M |
| Income/Loss From Continuing Operations Before Tax | -$153.72M |
| Income Tax Expense/Benefit | -$115.00K |
| Net Income/Loss | -$153.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$153.60M |
| Net Income/Loss Available To Common Stockholders, Basic | -$153.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$24.53 |
| Diluted Earnings Per Share | -$24.53 |
| Basic Average Shares | 106,838,512 |
| Diluted Average Shares | 106,838,512 |
| Assets | $241.99M |
| Current Assets | $220.97M |
| Noncurrent Assets | $21.02M |
| Fixed Assets | $9.36M |
| Other Non-current Assets | $11.65M |
| Liabilities | $308.88M |
| Current Liabilities | $70.81M |
| Accounts Payable | $5.49M |
| Other Current Liabilities | $65.33M |
| Noncurrent Liabilities | $238.06M |
| Equity | -$66.89M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$66.89M |
| Liabilities And Equity | $241.99M |
| Net Cash Flow From Operating Activities | -$151.61M |
| Net Cash Flow From Operating Activities, Continuing | -$151.61M |
| Net Cash Flow From Investing Activities | $16.01M |
| Net Cash Flow From Investing Activities, Continuing | $16.01M |
| Net Cash Flow From Financing Activities | $103.05M |
| Net Cash Flow From Financing Activities, Continuing | $103.05M |
| Net Cash Flow | -$32.55M |
| Net Cash Flow, Continuing | -$32.55M |
| Comprehensive Income/Loss | -$153.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$153.69M |
| Other Comprehensive Income/Loss | -$56.95M |